SANGAMO THERAPEUTICS INC

SGMO NASDAQ

avigrossman95

Shooting star. Failed test of resistance. Time to short!!!

savepiginvest

Following on strong momentum after Novartis deal, Sangamo Therapeutics with strong open that looks set to breakout the stock from a long sustained downtrend

tradingbulls2

Setting up for a big move

ag5

Seems like a nice and quick play

st0nkz

Load up for the Gap up

st0nkz

biotech is on fire... don't fight the market this is a buy! portfolio is up a massive 40% in 30 days.

DigitalData

All, This is a GREAT stock that has an extremely clear bottom and only $7 which means options and just buy and selling is easy. Right now it is extremely obvious. Buy in around $4 to $4.75 UNLESS it breaks this upper resistance, but even if it does there are some resistance levels $9-$11 range. So I would be careful if you are bullish where it is at now.

st0nkz

Probably will be more dips soon

tonyli86

The stock is still in early stage of the upward recovery trajectory and has managed to overcome its purple resistance level at $8.70. Mid-term resistance at $9.95 observed,while stronger resistance at $10.70.

savepiginvest

Look for sustained rally upwards from 50 day average, powerfull buy signal could be triggered and could move the stock closer to its consensus price target of $13.50 www.smarteranalyst.com NASDAQ:SGMO ...

st0nkz

Anyone else feel that this is undervalued?

shouhuiyang1983

long way to go $SGMO

st0nkz

buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it buy it

st0nkz

This company has been getting a lot of exposure in the buy-o-tech sektor. I have no idea what i'm doing but this looks like a winna 2 me.

st0nkz

BULLLLLLLLIIIIIIISSSSSSHHHHHH AF

st0nkz

.

follow_the_money

Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...